Mary Rinella to Risk Factors
This is a "connection" page, showing publications Mary Rinella has written about Risk Factors.
Connection Strength
1.318
-
Accuracy of the FIB-4 and LiverRisk score for use in primary risk assessment for liver fibrosis, and variation by age. Dig Liver Dis. 2026 07; 58(7):935-942.
Score: 0.110
-
Metabolic and Alcohol-Associated: Diagnosis and Management. Clin Liver Dis. 2026 Feb; 30(1):167-183.
Score: 0.105
-
Reply: People living with HIV and NAFLD and updated guidance on NAFLD screening. Hepatology. 2023 11 01; 78(5):E91-E92.
Score: 0.089
-
Recurrent NAFLD post-LT: Sisyphus' boulder or Proteus' parable? Liver Transpl. 2023 09 01; 29(9):917-918.
Score: 0.089
-
Factors Impacting Survival in Those Transplanted for NASH Cirrhosis: Data From the NailNASH Consortium. Clin Gastroenterol Hepatol. 2023 02; 21(2):445-455.e2.
Score: 0.082
-
Thanks to CLD for Small Favors: Reduced CVD Risk in Patients Awaiting Liver Transplantation. Dig Dis Sci. 2021 01; 66(1):7-9.
Score: 0.076
-
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020 05; 158(7):1851-1864.
Score: 0.071
-
The globalization of nonalcoholic fatty liver disease: Prevalence and impact on world health. Hepatology. 2016 07; 64(1):19-22.
Score: 0.054
-
Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016 Apr; 13(4):196-205.
Score: 0.054
-
Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
Score: 0.051
-
Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Int. 2015 Dec; 35(12):2575-83.
Score: 0.051
-
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma. Clin Liver Dis. 2015 May; 19(2):361-79.
Score: 0.050
-
Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012 Nov; 56(5):1741-50.
Score: 0.043
-
Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review. Liver Int. 2026 05; 46(5):e70608.
Score: 0.027
-
The Relentless Progression of Metabolic Dysfunction-associated Steatotic Liver Disease in Liver Transplantation in Spain. Transplantation. 2026 Feb 01; 110(2):e444-e452.
Score: 0.026
-
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025 11; 10(11):998-1012.
Score: 0.026
-
Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis. J Gastroenterol. 2025 07; 60(7):891-904.
Score: 0.025
-
Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 06; 11(1):14.
Score: 0.025
-
Risk Stratification for Chronic Kidney Disease After Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Cirrhosis: Results From the NailMASH Consortium. Transplantation. 2025 03 01; 109(3):484-495.
Score: 0.025
-
Preparing for the NASH Epidemic: A Call to Action. Gastroenterology. 2021 09; 161(3):1030-1042.e8.
Score: 0.020
-
Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-effective: A Comprehensive Cost-Utility Analysis. Gastroenterology. 2020 11; 159(5):1985-1987.e4.
Score: 0.018
-
Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020 08; 52(3):513-526.
Score: 0.018
-
Sex Hormone-Binding Globulin Levels in Young Men Are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2019 05; 114(5):758-763.
Score: 0.017
-
Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis. Liver Int. 2019 05; 39(5):933-940.
Score: 0.016
-
Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018 10; 48(7):696-703.
Score: 0.016
-
Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018 07; 24(7):908-922.
Score: 0.016
-
International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients. Transplantation. 2018 05; 102(5):727-743.
Score: 0.016
-
Twenty-five-year trajectories of insulin resistance and pancreatic ß-cell response and diabetes risk in nonalcoholic fatty liver disease. Liver Int. 2018 11; 38(11):2069-2081.
Score: 0.016
-
Outcomes of Early Liver Transplantation for Patients With Severe Alcoholic Hepatitis. Gastroenterology. 2018 08; 155(2):422-430.e1.
Score: 0.016
-
Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. Transplantation. 2017 12; 101(12):2873-2882.
Score: 0.015
-
Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int. 2018 04; 38(4):706-714.
Score: 0.015
-
ASGE EndoVators Summit: Defining the role and value of endoscopic therapies in obesity management. Gastrointest Endosc. 2017 11; 86(5):757-767.
Score: 0.015
-
Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2017 05; 112(5):755-762.
Score: 0.015
-
Factors associated with sustained virological response in liver transplant recipients with recurrent hepatitis C. Transplant Proc. 2010 Nov; 42(9):3647-51.
Score: 0.009